AXOVIA THERAPEUTICS LTD

Company Registration Number:
14715294 (England and Wales)

Unaudited abridged accounts for the year ended 31 December 2025

Period of accounts

Start date: 01 January 2025

End date: 31 December 2025

AXOVIA THERAPEUTICS LTD

Contents of the Financial Statements

for the Period Ended 31 December 2025

Balance sheet
Notes

AXOVIA THERAPEUTICS LTD

Balance sheet

As at 31 December 2025


Notes
2025
2024


£
£
Fixed assets
Investments: 3 644,613 644,613
Total fixed assets: 644,613 644,613
Current assets
Debtors: 4 417,778 463,133
Cash at bank and in hand: 2,682,552 4,569,651
Total current assets: 3,100,330 5,032,784
Creditors: amounts falling due within one year: 5 (238,597) (129,572)
Net current assets (liabilities): 2,861,733 4,903,212
Total assets less current liabilities: 3,506,346 5,547,825
Creditors: amounts falling due after more than one year: 6   (5,100,000)
Provision for liabilities: (288,617) (176,802)
Total net assets (liabilities): 3,217,729 271,023
Capital and reserves
Called up share capital: 433 263
Share premium account: 8,411,797 2,624,737
Profit and loss account: (5,194,501) (2,353,977)
Shareholders funds: 3,217,729 271,023

The notes form part of these financial statements

AXOVIA THERAPEUTICS LTD

Balance sheet statements

For the year ending 31 December 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 13 April 2026
and signed on behalf of the board by:

Name: Alek Safarian
Status: Director

The notes form part of these financial statements

AXOVIA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 December 2025

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

AXOVIA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 December 2025

2. Employees

2025 2024
Average number of employees during the period 8 8

AXOVIA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 December 2025

3. Fixed investments

Investments The Company has a fully owned subsidiary called Axovia Therapeutics, Inc. This Company is held at cost. It is assessed for impairment each year and any required changes will be recorded in the Profit and Loss account.

AXOVIA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 December 2025

4. Debtors

2025 2024
££
Debtors due after more than one year: 383,597 450,269

AXOVIA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 December 2025

5. Creditors: amounts falling due within one year note

As at 31 December 2025 creditors consists of £197,670 (2024: £81,964), which were amounts payable to a number of suppliers including for R&D services, consultants, and laboratory supplies in addition to an amount of £40,927 (2024: £47,608), which is held on behalf of Axovia Therapeutics, Inc.

AXOVIA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 December 2025

6. Creditors: amounts falling due after more than one year note

There was an 8% convertible loan note issued by the Company to ALSA Ventures I SCSp. On 21 October 2025, this loan was converted into Ordinary Shares. As such, as at 31st December 2025 £ Nil (2024: £5,100,000) was outstanding.

AXOVIA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 December 2025

7. Related party transactions

Philip Beales and Victor Hernandez were previously consultants and are now employees. They own 13,125 A Ordinary Shares each in the Company.